AEON Biopharma, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.274 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 13.67M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Details
| Name | AEON Biopharma, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 8 |
| Ceo | Robert Bancroft |
| Country | United States |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US00791X2099 |
| Cusip | 00791X209 |
| Cik | 1837607 |
| Sic | 2834 |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
Key executives
| Name | Title |
|---|---|
| Robert Bancroft | President, Chief Executive Officer and Director |
| Alex Wilson | Chief Legal and Strategy Officer and Corporate Secretary |
| Dr. Chad K. Oh M.D. | Chief Medical Officer |
| John A. Bencich M.B.A. | Chief Financial Officer |
| Jennifer Sy | Chief Accounting Officer |
| Dr. Paul Lee M.D., Ph.D. | Chief Regulatory Officer |
Contact
| Address | 5 Park Plaza, Suite 1750, Irvine, California 92614, United States |
| Phone | 949 354 6499 |
| Website | https://www.aeonbiopharma.com |